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The Pro12Ala polymorphism of the gene encoding the
peroxisome proliferator–activated receptor (PPAR)-2
has recently been shown to be associated with type 2
diabetes. In the present analysis, we investigated
whether PPAR-2 Pro12Ala was associated with micro-
vascular complications of type 2 diabetes, such as albu-
minuria, end-stage renal failure (ESRF), or retinopathy.
A total of 445 patients with type 2 diabetes who were
enrolled in the Berlin Diabetes Mellitus Study and in
whom we determined albuminuria and the presence of
ESRF and retinopathy were genotyped for the PPAR-2
Pro12Ala polymorphism. We also measured potentially
important covariables, such as blood pressure, BMI,
duration of diabetes, glycosylated hemoglobin, serum
creatinine, and serum lipids. Among 445 patients with
type 2 diabetes (mean age 59.3 years), the Pro12Ala
genotype distribution was in Hardy-Weinberg equilib-
rium (P  0.42). The Ala12 allele frequency was 0.14.
With adjustment for covariables, the 118 Ala12 allele
carriers had significantly lower urinary albumin excre-
tion (UAE) than the 327 noncarriers (17.1 vs. 25.8 mg/d;
P  0.01). The percentage decrease in UAE observed in
PPAR- Ala12 allele carriers relative to noncarriers
(P  0.003) rose from 0.2% (P  0.99) to 54% (P 
0.008) and to 70% (P  0.01) when the duration of
diabetes increased from <10 years to 10–19 years and
to >20 years, respectively. Similarly, the odds ratios of
having albuminuria decreased from 1.22 (P  0.54) to
0.61 (P  0.23) and to 0.11 (P  0.007), respectively.
Among patients with type 2 diabetes, PPAR-2 Ala12
allele carriers had significantly lower UAE and tended
to develop overt proteinuria less frequently. These
observations suggest a protective effect of the Ala12
allele in relation to diabetic nephropathy. Diabetes 51:
2653–2657, 2002
Type 2 diabetes constitutes a major health prob-lem and in most populations substantially con-tributes to morbidity and mortality (1). Itscomplications include macrovascular disorders
such as coronary artery disease (CAD) and microvascular
lesions such as neuropathy, retinopathy, and nephropathy.
Diabetic nephropathy, characterized by increased urinary
albumin excretion (UAE) or microalbuminuria (2,3), can
be viewed as a pathophysiologically complex phenotype.
It is a harbinger of deleterious cardiovascular and renal
outcomes (4,5). Furthermore, the incidence of end-stage
renal failure (ESRF) as a consequence of diabetic ne-
phropathy is rapidly increasing worldwide (6). One imme-
diate challenge, therefore, is to identify risk factors that
contribute not only to type 2 diabetes as such but also to
disease-related phenotypes, such as diabetic nephropathy.
Indeed, identification of common genetic factors that
influence outcome might help health care providers in the
early detection and treatment of potentially life-threaten-
ing disease conditions.
Diabetic nephropathy (7), as well as higher UAE rates,
clusters among offspring of patients with type 2 diabetes
(8); the risk of developing diabetic nephropathy has been
linked to different chromosomes, including chromosome 3
(9,10), to which the peroxisome proliferator–activated
receptor (PPAR)-2 gene has been mapped. PPAR-2,
expressed in vascular smooth muscle cells, mesangial
cells, and macrophages, is a ligand-activated transcription
factor and a member of the steroid receptor superfamily
(11), which has been shown to be involved in lipid and
glucose metabolism, fatty acid transport, and cell differ-
entiation (12). Most interesting is that recently developed
compounds such as the thiazolidinediones (TZDs) act as
PPAR- ligands (13,14) and have been reported to de-
crease albuminuria in patients with early diabetic ne-
phropathy (15), possibly pointing to a role of PPAR- in
the development of this disease-associated microvascular
phenotype. We therefore investigated whether Pro12Ala, a
recently identified functional genetic polymorphism in the
PPAR-2 gene and previously reported to be associated
with type 2 diabetes (16), was also related to type 2
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diabetes–associated disease phenotypes in patients of
European ancestry.
RESEARCH DESIGN AND METHODS
Patient selection and clinical investigation. Patients who had type 2
diabetes (n  445) and were of Caucasian ethnicity were recruited from three
diabetes and two dialysis centers as well as two general hospitals in Berlin
within the framework of the Berlin Diabetes Mellitus (BeDiaM) Study.
Classification of type 2 diabetes relied on the revised diagnostic criteria
recommended by the American Diabetes Association (17). The diagnosis of
nephropathy was based on repeated observation of UAE of 20 g/min in
nonoliguric patients or on the presence of ESRF necessitating renal replace-
ment therapy (dialysis or transplantation). Macroalbuminuria was defined as
UAE 200 g/min. Other causes of increased albumin excretion were
excluded by appropriate clinical and technical investigation. In agreement
with recently published World Health Organization criteria (18), hypertension
was defined as a systolic pressure of140 mmHg or diastolic pressure of90
mmHg on at least two separate occasions or as the necessity to prescribe
antihypertensive drugs, irrespective of the blood pressure level. An investiga-
tor unaware of the patient’s genotype searched the medical records for history
of CAD, stroke, or retinopathy. The diagnosis of CAD required a history of
myocardial infarction, coronary angioplasty or bypass surgery, coronary
lesions on angiography, or treatment with nitrates or a clinical history of
angina pectoris. Retinopathy was defined as stages III or IV on funduscopy or
as history of laser therapy. Serum creatinine, serum lipids, and glycosylated
hemoglobin (HbA1c) were determined by standard laboratory techniques.
The study protocol was approved by the institutional Ethics Committee. All
subjects gave informed consent before their enrollment in the study.
Statistical analysis. We used SAS version 8.1 (SAS Institute, Cary, NC) for
database management and statistical analysis. Measurements with a skewed
distribution were normalized by logarithmic transformation. Comparisons of
means and proportions were performed with the standard normal Z test and
Fisher’s exact test, respectively. Significant covariables were traced by
stepwise linear or logistic regression. We used analysis of covariance to
compare adjusted continuous measurements between genotypes. The pres-
ence of mild renal dysfunction in relation to genotype was studied by multiple
logistic regression.
Genotyping. Genomic DNA was prepared from peripheral blood using a
DNA-selective preparation method (Qiagen, Hilden, Germany). The region
encompassing the Pro12Ala polymorphic site was amplified by PCR as
previously described (16). PCR products were digested using the restriction
enzyme BstU-1 and visualized on ultraviolet-transilluminated ethidium bro-
mide–stained agarose gels.
RESULTS
PPAR-2 Pro12Ala polymorphism is related to UAE
and macroalbuminuria in patients with type 2 diabe-
tes. The clinical characteristics of 220 men and 225
women with type 2 diabetes are presented in Table 1. On
average, women were older than men and had a higher
serum creatinine concentration. Women were more fre-
quently hypertensive but in fewer instances proceeded to
ESRF.
The genotypic distribution of the PPAR-2 Pro12Ala
gene polymorphism was in Hardy-Weinberg equilibrium
(P  0.42), and the Ala12 allele frequency in our diabetes
population was 0.14 (Table 2).
Among our patients with type 2 diabetes, the 118 Ala12
carriers showed a significantly lower UAE than the 327
noncarriers (17.1 g/min [95% confidence interval (CI)
13.5–21.8 g/min] vs. 25.8 g/min [95% CI 21.9–30.4 g/
min]; P 0.01) (data not shown). With adjustment for sex,
age, BMI, hypertension, hyperlipidemia, duration of diabe-
tes, and treatment with insulin or oral antidiabetic drugs,
the percentage difference was 32% (95% CI 8–50%; P 
TABLE 1
Characteristics of 445 patients with diabetes
Men (n  220) Women (n  225)
Age (years) 57.8 9.8 60.6 10.3*
BMI (kg/m2) 27.6 4.1 28.5 5.5
Duration of diabetes (years) 10 (4–16) 10 (5–17)
Insulin treatment 139 (63.2) 161 (71.6)
Intake of antidiabetic drugs 131 (61.4) 121 (53.8)
HbA1c (%) 8.3  1.7 8.4  1.8
Serum creatinine (mol/l) 73.6 (71.3–75.9) 61.3 (59.0–63.6)*
UAE (g/min) 24.8 (20.3–30.2) 21.8 (18.0–26.5)
Macroalbuminuria 94 (42.7) 103 (45.8)
ESRF 30 (13.6) 14 (6.2)*
Retinopathy 36 (16.7) 33 (15.1)
Hypertension 80 (36.4) 120 (53.3)*
Systolic blood pressure (mmHg) 137.3 17.2 140.9  21.3
Diastolic blood pressure (mmHg) 80.0 8.1 80.6 10.7
Serum total cholesterol (mmol/l) 5.8 1.2 5.9  1.2
Serum triglycerides (mmol/l) 5.3 3.3 4.7  3.4
Cardiovascular complications 52 (23.6) 53 (23.6)
Data are arithmetic means  SD, medians (interquartile range) (for duration of diabetes), geometric means (95% CI for serum creatinine and
UAE), or n (%). Serum lipids were measured in 172 men and 190 women. *P  0.01 vs. men.
TABLE 2
Genotype and allele frequencies in patients with and without microvascular complications
ProPro ProAla AlaAla P* Pro Ala P*
No microvascular complications 144 (70.9) 55 (27.1) 4 (2.0) — 343 (84.5) 63 (15.5) —
Macroalbuminuria 154 (78.2) 37 (18.8) 6 (3.0) 0.12 345 (87.6) 49 (12.4) 0.22
ESRF 30 (68.2) 13 (29.5) 1 (2.3) 0.88 73 (83.0) 15 (17.0) 0.75
Retinopathy 55 (79.7) 13 (18.8) 1 (1.5) 0.33 123 (89.1) 15 (10.9) 0.20
Data are n (%). *For comparison with group without microvascular complications.
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0.01) (Fig. 1). Furthermore, the percentage difference in
UAE between Ala12 allele carriers and noncarriers in-
creased (P  0.003) with longer duration of diabetes (Fig.
1). With similar adjustments as mentioned above, the
percentage difference was 54% in patients with diabetes
and a disease history from 10 to 19 years (95% CI 20–74%;
P  0.008) and 70% in those who had diabetes for 20
years (95% CI 24–88%; P  0.01). In contrast, among those
patients in whom diabetes was diagnosed within the past
10 years, there was no difference in UAE with respect to
the different Pro12Ala genotypes (P  0.99) (Fig. 1).
We also calculated the odds ratio of having proteinuria
coded as a dichotomous trait (0, 1) with adjustments for
the same covariables as in the continuous analysis. In all
445 patients, the odds ratio was 0.66 for Ala12 allele
carriers compared with noncarriers (95% CI 0.42–1.04; P
0.07) (Table 3), which just failed to reach statistical
significance because of a significant interaction (P 
0.003) (Fig. 2) between the Pro12Ala polymorphism and
the duration of diabetes. Indeed, the odds ratio decreased
from 1.22 (95% CI 0.64–2.32; P  0.54) to 0.11 (95% CI
0.02–0.55; P  0.007) in patients in whom the disease
history was 10 years compared with those who had
diabetes for 20 years.
There was no significant association of the PPAR-2
Pro12Ala polymorphism with any other measured pheno-
type in the BeDiaM Study, including ESRF or diabetic
retinopathy, before and after allowing for the duration of
diabetes.
DISCUSSION
The main finding of the present study was that among
patients with type 2 diabetes, PPAR-2 Ala12 allele carri-
ers had significantly lower UAE and presented less fre-
quently with macroalbuminuria. This suggests a role of
genetic variation in the PPAR-2 gene in the development
of diabetes-related nephropathy. The strength of the asso-
ciation increased with longer duration of diabetes, a
phenotype that is likely to represent a surrogate of envi-
ronmental factors that over time modulate the genetic
FIG. 1. Percentage difference in UAE between PPAR-2 Ala12 allele
carriers and noncarriers for all patients and for subgroups according to
duration of diabetes. Differences were adjusted for sex, age, BMI,
hypertension, hyperlipidemia, duration of diabetes, and treatment with
insulin or oral antidiabetic drugs. Vertical lines denote 95% CI. For
each subgroup, the number of subjects is given (bottom). Number of
patients (n) and significance levels for the difference (P) and for the
interaction (Pint) between the genetic polymorphism and duration of
diabetes are given.
FIG. 2. Odds ratios of having macroalbuminuria in PPAR-2 Ala12
allele carriers versus noncarriers for all patients and subgroups ac-
cording to duration of diabetes. The odds ratios were adjusted for sex,
age, BMI, hypertension, hyperlipidemia, duration of diabetes, and
treatment with insulin or oral antidiabetic drugs. Vertical lines denote
95% CI. The size of the symbols is proportional to the number of cases
given alongside the squares. Number of patients (n) and significance
levels for odds ratios (P) and for the interaction (Pint) between the
genetic polymorphism and duration of diabetes are given.
TABLE 3
Association between microvascular complications of diabetes and the PPAR-2 Pro12Ala polymorphism
ProPro (n  327) AlaAlaAlaPro (n  118) Relative risk (95% CI)* P
Macroalbuminuria 47.1 (154) 36.4 (43) 0.66 (0.42, 1.04) 0.07
ESRF 9.2 (30) 11.9 (14) 1.27 (0.63, 2.57) 0.51
Retinopathy 16.8 (55) 11.9 (14) 0.64 (0.32, 1.27) 0.20
Data are % (n) unless otherwise indicated. *The odds ratios of having microvascular disease (ProAlaAlaAla versus ProPro) were adjusted
for sex, age, BMI, hypertension, hyperlipidemia, duration of diabetes, and treatment with insulin or oral antidiabetic drugs.
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impact on diabetic nephropathy. The reason that we were
not able to show an association between ESRF and
Pro12Ala in our patients with type 2 diabetes might be
related to the fact that ESRF is a more complex phenotype
that is determined by a plethora of different pathophysio-
logical as well as genetic factors. However, patients with
type 2 diabetes have an excessive cardiovascular risk,
leading to a dramatically reduced survival before ESRF
develops (6,19), therefore introducing a bias toward low
ESRF rates that hampers the unraveling of the underlying
genetic risk factors. In the development of diabetic ne-
phropathy, morphologic changes such as thickening of the
glomerular basement membrane, glomerular hypertrophy,
mesangial expansion, and modest expansion of the tubu-
lointerstitium play a role. All of these factors lead to
microalbuminuria as a diagnostic hallmark of diabetic
nephropathy, preceding the development of overt protein-
uria (20).
The risk of developing diabetic nephropathy is likely to
be genetically determined, because not all patients share
the same renal outcome even when obviously presenting
with the same degree of metabolic dysregulation. In this
regard, the prevalence of microalbuminuria has been
reported to be significantly higher in Mexican-American
than in non-Hispanic white diabetic subjects (21,22), and
higher UAEs have been observed in offspring of patients
with type 2 diabetes (23). Strojek et al. (8) recently
reported higher UAE rates in healthy offspring of diabetic
parents with nephropathy versus those without nephrop-
athy. Furthermore, the risk of developing diabetic ne-
phropathy has been linked to different chromosomes,
including chromosome 3 (10), on which the gene encoding
PPAR-2 is located.
Recently developed compounds such as TZDs act as
potent PPAR- ligands and have been shown to ameliorate
microalbuminuria in patients with early diabetic nephrop-
athy (15). Nakamura et al. (24) recently observed that
TZDs reduce UAE in microalbuminuric patients as well as
the serum concentration of type IV collagen, whereas
glibenclamide showed no such effects. Other investigators
reported that TZDs lower microalbuminuria, possibly by
inhibiting platelet-derived growth factor–stimulated cell
growth and angiotensin II–induced plasminogen-activator
inhibitor (PAI)-1 expression, both of which are known to
contribute to the development of nephropathy (25).
The mechanisms by which PPAR-2 and variation in its
gene might actually protect against diabetic nephropathy
remain to be elucidated. Even if glomerular expression of
PPAR- has been reported (26,27), the major sites of
PPAR-2 expression are adipocytes (28). Adipocytes gen-
erate and secrete PAI-1 (29), angiotensin II, and type IV
collagen (30). In this respect, it is conceivable that a
reduced level of PPAR-2 activation in preadipocytes,
leading to reduced adipocyte differentiation, may be re-
sponsible for reduced levels of PAI-1, angiotensin II, and
type IV collagen in patients who carry the Ala12 allele of
PPAR-2, possibly resulting in renal protection.
In agreement with several other association studies
(31–33), on the PPAR-2 Pro12 allele and type 2 diabetes,
our results speak in favor of a protective effect of the Ala12
allele on diabetes-associated phenotypes, i.e., nephropa-
thy. The molecular mechanism by which the Ala12 carry-
ing PPAR-2 protein might achieve these beneficial
actions, which largely resemble the specific effects of
TZDs on diabetic nephropathy, remains to be elucidated.
In conclusion, among patients with type 2 diabetes,
PPAR-2 Ala12 allele carriers have significantly lower UAE
and develop overt proteinuria less frequently. These ob-
servations suggest a protective effect of the Ala12 allele in
relation to diabetic nephropathy. Whether TZDs as
PPAR- ligands might be more effective in patients with
type 2 diabetes who carry the PPAR-2 Pro12 risk allele
remains to be investigated in future clinical studies.
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